Infusion of CARv3-TEAM-E T Cells in Glioblastoma
New England Journal of Medicine · 2024
DOI: 10.1056/nejmc2405721 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Elizabeth R Gerstner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor: In a proof-of-concept phase 1 study involving three participants with glioblastoma, Choi et al. (April 11 issue) 1 intraventricularly administered CARv3-TEAM-E T cells (which are chimeric antigen receptor [CAR] T cells engineered to target the epidermal growth factor receptor [EGFR] variant III [EGFRvIII] tumor-specific antigen and the wild-type EGFR protein). The rationale for this therapy is based on the use of genetically engineered CAR T cells against truncated EGFRvIII, which is expressed in 25 to 60% of glioblastomas. 2,3 These CAR T cells also secreted T-cell–engaging antibody molecules (TEAMs) against full-length EGFR to boost efficacy. All three participants in . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston, MA.
Zitieren
APA
Gerstner, E. R., Choi, B. D., & Curry, W. T. (2024). Infusion of CARv3-TEAM-E T Cells in Glioblastoma. New England Journal of Medicine. https://doi.org/10.1056/nejmc2405721
Vancouver
Gerstner ER, Choi BD, Curry WT. Infusion of CARv3-TEAM-E T Cells in Glioblastoma. New England Journal of Medicine. 2024. doi:10.1056/nejmc2405721
BibTeX
@article{Gerstner2024,
author = {Gerstner, Elizabeth R and Choi, Bryan D and Curry, William T},
title = {Infusion of CARv3-TEAM-E T Cells in Glioblastoma},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmc2405721}
}
EUVIMED